22 Jul
2021

Australian pharma patentees must remain vigilant on third-party damages

While recent court decisions have calmed fears of a growth in third-party lawsuits against life sciences patent litigants in Australia, the risk of disputes with insurers and state healthcare providers remains

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth